Integrated Diagnostics HoldingsLSE:IDHC 59 PS Ratio is 6.69 as of Jul. 06, 2026, which is 172% above its 10-year median of 2.46. GuruFocus rates LSE:IDHC with a GF Score™ of 59/100 and a GF Value™ of $0.59 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks worse than 78.22% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Integrated Diagnostics Holdings's share price is $0.502.
Integrated Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08. Hence, Integrated Diagnostics Holdings's PS Ratio for today is 6.69.
The historical rank and industry rank for Integrated Diagnostics Holdings's PS Ratio or its related term are showing as below:
LSE:IDHC'
s PS Ratio Range Over the Past 10 Years
Min: 1.34 Med: 2.46 Max: 21.85
Current: 6.69
During the past 13 years, Integrated Diagnostics Holdings's highest PS Ratio was 21.85. The lowest was 1.34. And the median was 2.46.
LSE:IDHC's PS Ratio is ranked worse than 78.22% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.855
vs LSE:IDHC: 6.69
During the past 13 years, Integrated Diagnostics Holdings's highest 3-Year average Revenue per Share Growth Rate was 45.70% per year. The lowest was -29.90% per year. And the median was -2.15% per year.
Back to Basics: PS Ratio
Integrated Diagnostics Holdings (LSE:IDHC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Integrated Diagnostics Holdings PS Ratio Related Terms
Integrated Diagnostics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's PS Ratio falls into.
Integrated Diagnostics Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Integrated Diagnostics Holdings's Share Price of today is $0.502. Integrated Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Integrated Diagnostics Holdings (LSE:IDHC) has a PS Ratio of 6.69 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Integrated Diagnostics Holdings and its competitors. This is 172% above median its historical median of 2.46. Over the past decade, Integrated Diagnostics Holdings' PS Ratio has ranged from 1.34 to 21.85. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #158 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 78.2%.
Is Integrated Diagnostics Holdings' PS Ratio too high?
Integrated Diagnostics Holdings' current PS Ratio of 6.69 is 172% above median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 21.85. The Medical Diagnostics & Research industry median PS Ratio is 2.86. Integrated Diagnostics Holdings' value of 6.69 is 134.3% above this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #158 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #158 out of 202 companies for PS Ratio. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median PS Ratio is 2.86. Integrated Diagnostics Holdings' value of 6.69 is 134.3% above this benchmark. Historically, Integrated Diagnostics Holdings' own PS Ratio has ranged from 1.34 to 21.85 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 2.86, Integrated Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current PS Ratio of 6.69 is 134.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current PS Ratio is 6.69, which is 172% above median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.50 — trading 14.9% below its estimated fair value. The current PS Ratio is 6.69, which is 172% above median its 10-year median of 2.46 and 134.3% above the Medical Diagnostics & Research industry median of 2.86. Integrated Diagnostics Holdings' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current PS Ratio is 6.69 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.50 is trading 14.9% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
PS Ratio: 6.69 (172% above median its 10-year median of 2.46)
GF Value™: $0.59 vs. price of $0.50 (14.9% below fair value)
Industry Position: 134.3% above the Medical Diagnostics & Research median (#158 of 202)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
59GF Score
Get the complete analysis for LSE:IDHC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
